Bend Research has licensed its spray-dried dispersion (SDD) technology to Eli Lilly and Co. This technology is designed to improve the bioavailability of compounds with low aqueous solubility and has been applied to hundreds of compounds at various stages of development. Lilly will also have access to Bend Research's portfolio of other drug delivery technologies.

Also, as part of an existing agreement, Bend Research will continue to provide formulation, development, analytical, engineering and manufacturing services to support Lilly’s preclinical and clinical development programs.

"This expansion in our relationship with Lilly is a great milestone for us," said Rod Ray, chief executive officer of Bend Research. "Our teams work well together and have a shared commitment to bring the best new medicines to caregivers and patients.  We believe this collaboration will add significant value to Lilly's research efforts and help them advance their compounds more quickly and efficiently."